Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report describes a case of alopecia universalis in a woman with hepatitis C linked to pegylated interferon alfa-2b and ribavirin therapy, with hair regrowth observed one year after discontinuation.

In this study, researchers reported that a newly developed interferon-γ release assay for cell-mediated immunity to SARS-CoV-2 nucleocapsid peptides demonstrated high sensitivity and specificity, making it a robust tool for routine diagnostic tests and potentially useful in predicting clinical outcomes after pathogen re-exposure.

This case report describes irreversible alopecia universalis following discontinuation of Peg-IFN/RBV treatment for chronic hepatitis C, highlighting potential autoimmune side effects of interferon-based therapies.

This article reports on a partial regrowth of scalp hair in a patient treated with extracorporeal photochemotherapy and interferon α 2a, but provides no new clinical outcomes.

In this clinical trial, patients with lichen planopilaris treated with the oral TYK2 inhibitor deucravacitinib showed significant improvement in PGA, LPPAI, and Skindex-16 scores over 24 weeks, with transcriptomic analyses indicating decreased inflammatory and immune pathway activity post-treatment.

This study found significantly higher levels of Toll-Like Receptor 4, interferon gamma, and interleukin-17 in Iraqi patients with alopecia areata compared to controls, suggesting these immune markers play a crucial role in the disease's development and could be targets for future treatments.

In this experimental study, laser irradiation significantly altered the gene expression of cytokines in cultured human T-cell lymphocytes, suggesting that such laser light may photobiomodulate cytokine production in vitro.

During treatment with interferon/ribavirin for hepatitis C, this study observed significant and lasting improvement in a patient's psoriasis without additional psoriasis-specific therapies.

In this study, pegylated interferon alpha therapy was independently associated with more severe hair loss, particularly acute telogen effluvium, in chronic hepatitis B patients with alopecia, compared to nucleos(t)ide analog therapy, emphasizing the importance of monitoring and counseling, especially for younger female patients.

This study found that patients with Alopecia Areata had significantly higher levels of the chemokines MIG and IP-10 compared to healthy controls, suggesting these molecules may serve as potential biomarkers for diagnosing and monitoring the condition.

In this study conducted at Baqiyatullah Hospital, it was found that interferon beta (IFNβ) treatment in multiple sclerosis patients commonly led to skin complications, with injection site erythema being most frequent, and also increased hair loss severity.

In this study, serum IL-13 and TGF-β concentrations were significantly different between alopecia areata patients and controls, suggesting a role for these cytokines in the disease's pathogenesis.

Some patients lost hair after taking interferon alpha 2B, but it improved for some while still on the treatment and for others after stopping it.

This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.

This study observed that two patients treated with interferon α-2b and ribavirin for chronic hepatitis C experienced complete and reversible straightening of their natural curly hair, which recurred with treatment resumption.

This case study describes the successful use of recombinant feline interferon-omega in managing feline chronic gingivostomatitis syndrome in cats with type II diabetes, where long-acting corticosteroids are contraindicated.

This study found that 87% of patients with stage IIA and IIB melanoma treated with low-dose alpha-interferon reported cutaneous side effects, with the most common being hair loss.

This review discusses the involvement of type I interferons in skin autoimmune and inflammatory diseases but reports no new clinical results.

In this study, a patient with clinically amyopathic dermatomyositis experienced persistent skin issues despite treatment, highlighting questions about type I interferon's role in skin disorders and potential IFN-targeted therapies for cutaneous lupus erythematosus and dermatomyositis.

This case study reports the first instance of irreversible alopecia universalis occurring during pegylated interferon-ribavirin therapy in a man with hepatitis C infection, without evidence of immunological or thyroid disorders.

In this report, a case of a bullous lesion developed at the injection site in a patient treated with PEG-IFN-α-2a for chronic hepatitis C was described.

The study identified increased IL-24 expression in keratinocytes and fibroblasts exposed to particulate matter, contributing to skin aging by promoting conditions similar to age-related changes such as increased MMP1 expression and decreased type I collagen production.

In this study, 97% of patients undergoing pegylated interferon alfa2a and ribavirin therapy for chronic hepatitis C experienced one or more skin-related side effects, with hair loss being the most common.

This letter to the editor discusses excessive hair growth observed around local β-interferon injection sites for malignant melanoma but reports no new clinical results.

This study demonstrated the expression of type 1 interferon-related proteins in inflammatory lesions of alopecia areata, showing a distinct distribution pattern compared to cicatricial alopecia.

This report documents the first known case of acute inflammatory demyelinating polyneuropathy potentially linked to pegylated interferon-alpha 2a in a woman undergoing treatment for chronic hepatitis C.

This study observed that inflammatory AIGA is associated with sweat duct inflammation and sweat coil atrophy, while non-inflammatory AIGA involves only sweat coil atrophy, suggesting distinct pathological features between the two.

In this study, researchers examined chronic hepatitis B patients and found that those undergoing interferon therapy reported higher quality of life than those on non-antiviral or nucleoside/nucleotide analogue treatments, despite potential side effects.

This study found that patients taking hydroxychloroquine had a significantly higher likelihood of indeterminate QuantiFERON-TB Gold test results compared to those not on the medication, independent of other immunosuppressive drug use.